Mr. Xuechu He, who was named #38 on Forbes richest Chinese list in 2010 with a new worth of RMB 12 billion, purchased a stake in You On Demand Holdings, Inc. (NASDAQ:YOD) from C Media Limited (“C Media”), a leading mobile video service provider in China, in a private stock transaction. Mr. He purchased 2,285,715 restricted Series E convertible preferred shares. You On Demand Holdings, Inc. (NASDAQ:YOD) shares after opening at $2.32 on last trade day and at the end of the day closed at $3.23. Company price to sales ratio in past twelve months was calculated as 178.30 and price to cash ratio as 14.08. You On Demand Holdings, Inc. (NASDAQ:YOD) showed a positive weekly performance of 29.20%.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) shares were up on positive top-line data from a mid-stage study on its experimental anti-coagulant, ISIS-FXIRx. The company presented results from a global, multi-center, open-label, comparator-controlled phase II study in patients undergoing total knee replacement surgery or total knee arthroplasty (TKA). Two doses of ISIS-FXIRx (200mg, 300mg) were compared to Sanofi’s Lovenox (enoxaparin). ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) shares advanced 11.46% in last trading session and ended the day on $27.81. ISIS return on equity ratio is recorded as -18.10% and its return on assets is -8.10%. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) yearly performance is 34.74%.
On May 20, 2014, Prosensa Holding NV (NASDAQ:RNA) reported financial results for the first quarter ending March 31, 2014 and provided an update on the next steps for its exon-skipping platform for the treatment of Duchenne Muscular Dystrophy (DMD). Prosensa Holding NV (NASDAQ:RNA) shares moved up 27.04% in last trading session and was closed at $8.41, while trading in range of $7.65 – $8.96. Prosensa Holding NV (NASDAQ:RNA) year to date (YTD) performance is 80.09%.
On May 7, 2014, Novavax, Inc. (NASDAQ:NVAX) reported its financial results for the first quarter ended March 31, 2014. Delivered positive top-line data from a dose-confirmatory Phase 2 clinical trial of its RSV F-protein vaccine candidate in 720 women of childbearing age, showing: Vaccine candidate was well-tolerated with no vaccine-related serious adverse events; Highest immune responses observed with a single dose of vaccine combined with aluminum phosphate adjuvant. Novavax, Inc. (NASDAQ:NVAX) weekly performance is 16.87%. On last trading day company shares ended up $4.85. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average (SMA50) is 11.68%. Analysts mean target price for the company is $11.00.
On May 13, 2014, Wave Systems Corp. (NASDAQ: WAVX) announced that its management software has been validated for use with SanDisk’s new self-encrypting solid state drive (SSD) for corporate environments, the SanDisk X300s SSD. Wave Systems Corp. (NASDAQ:WAVX) shares after opening at $1.92 on last trade day and at the end of the day closed at $2.03. Company price to sales ratio in past twelve months was calculated as 3.37 and price to cash ratio as 39.14. Wave Systems Corp. (NASDAQ:WAVX) showed a positive weekly performance of 39.04%.